Jeremy Yarwood, Chief Scientific Officer of Neogen Corp, filed a Form 4 on November 4, 2026, disclosing a sequence of RSU vesting, tax withholding, and an open-market sale that reduced his direct beneficial ownership of common stock to zero shares.

Key Highlights

  • RSU vest: 16,207 shares of Neogen Corp common stock were acquired by Yarwood on November 3, 2026, via an M-coded transaction at a price of $11.82 per share.
  • Tax withholding: 7,156 shares were withheld on November 3, 2026, also at $11.82 per share, to cover taxes on the vested RSUs, leaving 9,051 shares directly held.
  • Open-market sale: All remaining 9,051 shares were sold on November 4, 2026, at $12.67 per share, coded as an S transaction.
  • Resulting ownership: Following all reported transactions, Yarwood's direct beneficial ownership of Neogen Corp common stock stands at 0 shares.
  • Filer role: Jeremy Yarwood is identified in the filing as Chief Scientific Officer of Neogen Corp (NASDAQ:NEOG).
  • Signing authority: The form was signed by Christopher Sefcheck as attorney in fact, dated November 4, 2026.

Yarwood RSU Vesting and Full Share Disposition at Neogen Corp

According to the filing, the sequence of transactions began on November 3, 2026, when 16,207 shares of Neogen Corp common stock were acquired by Jeremy Yarwood through the vesting of restricted stock units (RSUs), recorded at a price of $11.82 per share. The filing notes that "RSUs vested on the anniversary of the grant date." Immediately following, 7,156 shares were withheld at the same price of $11.82 per share to cover taxes associated with the vested shares, an F-coded transaction consistent with tax withholding upon vesting.

After the withholding, Yarwood's direct holdings stood at 9,051 shares. On November 4, 2026, all 9,051 of those shares were disposed of in an open-market sale at $12.67 per share, coded as an S transaction. No indirect holdings or derivative securities are reported in the filing. Following all reported transactions, the filing shows Yarwood's direct beneficial ownership of Neogen Corp common stock at 0 shares.

The Form 4 was filed on behalf of Yarwood by Christopher Sefcheck, identified as attorney in fact, and dated November 4, 2026. The filing does not indicate whether a Rule 10b5-1 trading plan governed any of the reported transactions; the corresponding checkbox on the form is not checked.

What Was Disclosed

The filing disclosed three transactions by Neogen Corp Chief Scientific Officer Jeremy Yarwood: an RSU vest of 16,207 shares, a tax-withholding disposition of 7,156 shares, and an open-market sale of 9,051 shares, leaving zero direct beneficial ownership.